Sunday 18 October 2026
Export FENC’s income statement to Excel — free account
Adherex Technologies Inc.
FENC Healthcare Biotechnology
Adherex Technologies Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 million, down 6.09% from fiscal 2024. In the quarter to June 2026, revenue grew 85.2%, EPS grew 154.6% and free cash flow grew 101.4%, each against the same quarter a year earlier.
9.98
0.37
−3.57%
Follow FENC
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
6.73 | 4.93 | 4.14 | 6.27 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
174.84 | (36.91) | 88.76 | 7,427.18 | |
P/B ratio |
0.00 | 6.20 | 5.60 | 8.75 | |
Price to Tangible BV |
0.00 | 6.20 | 5.60 | 8.75 | |
EV/Sales |
6.64 | 4.52 | 3.71 | 5.88 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(32.24) | (16.16) | (32.78) | (170.82) | |
EV/FCF |
(32.24) | (16.16) | (32.78) | (170.82) | |
Quick Ratio |
4.21 | 5.71 | 6.15 | 5.21 | |
Current Ratio |
4.69 | 6.37 | 6.98 | 5.85 | |
Net Debt/EBITDA |
25.44 | 14.72 | 432.03 | (23.41) | |
Debt/Assets |
36.76% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
(4.03) | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.72 | 0.77 | 0.86 | 0.98 | |
Operating CF/Net income |
(2.34) | 1.25 | 11.84 | 0.03 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(0.32) | (8.29) | (17.00) | 579.00 | |
Research and Development Expense of Revenue |
0.23% | 0.15% | 0.32% | 0.66% | |
Selling, General and Administrative Expense of Revenue |
95.99% | 105.58% | 96.69% | 85.59% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
17.81% | 18.31% | 6.55% | 9.93% | |
Graham Net Nets |
(0.03) | 0.15 | 0.16 | 0.11 | |
Graham Number |
0.91 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(2.46%) | (4.42%) | (4.78%) | (1.15%) | |
Free Cash Flow Yield |
(3.06%) | (5.67%) | (2.74%) | (0.55%) | |
Revenue per Share |
0.45 | 0.48 | 0.44 | 0.52 | |
Operating CF per Share |
0.05 | (0.21) | 0.07 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.05 | (0.21) | 0.07 | 0.00 | |
Cash per Share |
0.79 | 1.29 | 1.17 | 1.19 | |
Shareholders Equity per Share |
(0.16) | 1.24 | 1.10 | 1.23 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.16) | 1.24 | 1.10 | 1.23 | |
Free Cash Flow |
1.49 | (5.96) | 2.38 | 0.05 | |
Working Capital |
36.25 | 56.53 | 57.29 | 60.11 | |
Net Current Asset Value |
(7.69) | 31.96 | 32.73 | 39.19 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
16.13 | 18.05 | 17.11 | 20.38 | |
Average Payables |
4.87 | 3.94 | 5.78 | 5.73 | |
Average Inventory |
1.80 | 1.31 | 1.63 | 2.29 | |
Average Assets |
54.09 | 57.75 | 59.11 | 60.31 | |
Average Common Equity |
(4.83) | 14.80 | 15.90 | 17.49 |
Columns are period end dates